Home / Conditions / Pudendal Neuralgia
Pudendal Neuralgia: when insurers say no, reviewers often say yes
In 12 published external-review decisions involving pudendal neuralgia, independent physician reviewers overturned the insurer’s denial 33.3% of the time.
Published decisions
12
2001–2026
Overturned
33.3%
4 denials reversed
Most-fought treatments for pudendal neuralgia
What insurers denied — and how those fights ended.
| Category | Decisions | Overturned |
|---|---|---|
| Physical Therapy | 3 | 66.7% |
What the insurer actually argued
Denials fall into different categories, and they don’t succeed equally — so the reason on your letter changes how you should answer it.
| Reason given | Decisions | Overturned |
|---|---|---|
Medical Necessity The plan said the care wasn’t medically necessary. The most common fight, and the most winnable. | 9 | 33.3% |
Experimental/Investigational The plan called the treatment unproven. These turn on published evidence, so the appeal is a literature argument. | 3 | 33.3% |
Typical time to a decision
6 days
Most land between 2 and 21 days
Handled as urgent
50%
Expedited when a delay would cause harm
What the reviewers wrote
Excerpts from the independent reviewers’ published findings — the actual reasoning, quoted, not summarised.
Where the denial was overturned
Nature of Statutory Criteria/Case Summary: An enrollee has requested authorization and coverage for pudendal nerve stimulation with StimWave neuromodulation (Phase 1 – percutaneous implantation of neurostimulator electrode, peripheral nerve and Phase 2 – insertion/replacement of peripheral neurostimulator pulse generator or receiver. In the medical literature, Murer and colleagues evaluated current studies on the treatment options available for patients with pudendal neuralgia (PN). The authors concluded that, “Although there are a number of modalities utilized for the treatment of PN, there are no current recommendations based on treatment efficacies.” Fang and colleagues reported on 80 patients with pudendal neuralgia who were treated with pulsed radiofrequency and pudendal nerve block or nerve block alone.
Nature of Statutory Criteria/Case Summary: The patient has requested authorization and coverage for Nucynta 100 mg tablet (#120 per 30 days) and oxymorphone extended-release 10 mg tablet (#90 per 30 days). The Centers for Disease Control and Prevention (CDC) guidelines state that, “Nonpharmacologic therapy and nonopioid pharmacologic therapy are preferred for chronic pain. Clinicians should consider opioid therapy only if expected benefits for both pain and function are anticipated to outweigh risks to the patient.
Where the denial was upheld
Worth reading too — these show what an appeal has to overcome.
Findings: The physician reviewer found that Nature of Statutory Criteria/Case Summary: The patient has requested authorization and coverage for nerve ablation procedure of the obturator internus nerve. Regarding the use of radiofrequency ablation for pelvic pain due to pudendal neuralgia, researchers report that options to consider include cryoablation and pulsed radiofrequency ablation. The authors cited a study of computed tomography (CT)-guided cryoablation that included 11 patients, noting that the results showed a decrease of pain on a 10-point scale from an average of 7.6 pre-procedure to 3.1 at six months posttreatment. The authors cited another study of 26 patients undergoing pulsed radiofrequency ablation of the pudendal nerve under CT guidance that demonstrated a decrease of pain on a 10-point scale from an average of 9 pre-procedure to 1.9 at one year posttreatment.
Findings: The physician reviewer found that Nature of Statutory Criteria/Case Summary: A patient has requested authorization and coverage for radiofrequency ablation (RFA). With regards to the evidence surrounding pudendal nerve treatment, one review noted that although surgery seems to provide a higher proportion of long-term benefits, identifying the most efficient therapeutic approach is made difficult by the multitude of outcome measurements and follow-up frequencies. The authors also note that “literature is sparse regarding randomized controlled trials with long-term follow-up”. Another review concluded that, “Emerging techniques such as pulsed radiofrequency ablation… are promising; however, more studies are needed to evaluate safety and effectiveness. Current study data is generally poor, and unstandardized.
Figures and quotations on this page come from 42,749 published decisions in the California DMHC Independent Medical Review dataset. These are California outcomes — every state runs an equivalent external review, but the rates here are California’s. Excerpts are quoted verbatim from the public record and describe this condition generally, not any individual case.
How to use this in your appeal
These outcomes come from California’s external review program — an independent physician panel whose decision binds the insurer. Every state has an equivalent, and internal appeals succeed even more often. If your care for pudendal neuralgia was denied, the published record says the denial is worth fighting.
SOURCE: CALIFORNIA DMHC INDEPENDENT MEDICAL REVIEW OUTCOMES (CHHS OPEN DATA) · DERIVED AGGREGATE STATISTICS ONLY · METHODOLOGY
Not legal or medical advice. Coverage Rights is a self-help tool that helps you prepare your own appeal. For advice about your specific situation, talk to a licensed attorney or your doctor.